DF102



NAME OF DRUG : DF102

ALSO KNOWN AS : AF102

LABORATORY : AFIMMUNE

STATUS AND ADVANCEMENT

Type of drug : Undefined mechanism

Clinical trials advancement : Initiating Phase 2a

The drug got the Fast Track Status granted by the FDA

Estimated time to market : 99 months.

LABORATORY ABSTRACT ON THE DRUG

NOT PROVIDED

RECENT NEWS ON DF102

2017-03-29 : Afimmune’s DS102 receives FDA fast track designation as an investigational treatment for patients suffering from NASH with liver fibrosis

SOME PUBLICATIONS RELATED WITH DF102

SOME NASHBIOTECHS POINTS OF VIEW RELATED WITH DF102


WWW.NASHBIOTECHS.COM  -  Copyright G DIVRY 2015-2016  - Contact and TERMS OF USE